Navigation Links
Moody's Upgrades Mylan
Date:3/11/2011

PITTSBURGH, March 11, 2011 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today reported that Moody's Investors Service ("Moody's") has upgraded the company's credit ratings, including the "Corporate Family Rating," to Ba2 from Ba3 (positive outlook). Following this action, Moody's rating outlook is stable.  

According to Moody's: "Moody's upgrade of Mylan reflects improving earnings trends accomplished through new product launches, a strong global generics footprint, and good vertical integration… Mylan's Ba2 Corporate Family Rating continues to reflect good size and scale as the #3 player in the global generics pharmaceutical industry, a solid global generic drug pipeline, and revenue diversity from the specialty branded segment."

Mylan's Chief Financial Officer John Sheehan commented: "Moody's upgrade of Mylan's credit ratings follows a similar positive upgrade by S&P yesterday. We are gratified that independent third parties such as these ratings agencies recognize the strength of Mylan's diversified business and favorable position within the generics industry, as well as the company's continued potential for growth."

Mylan Inc. ranks among the leading generic and specialty pharmaceutical companies in the world and provides products to customers in more than 150 countries and territories. The company maintains one of the industry's broadest and highest quality product portfolios supported by a robust product pipeline; operates one of the world's largest active pharmaceutical ingredient manufacturers; and runs a specialty business focused on respiratory, allergy and psychiatric therapies. For more information about Mylan, please visit www.mylan.com.

Forward Looking Statements

This press release includes statements that constitute "forward-looking statements," including with regard to the company's anticipated growth. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the impacts of competition; changes in economic and financial conditions of the company's business; uncertainties and matters beyond the control of management; and the other risks detailed in the company's filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Smart Sense(TM) From RF Technologies Upgrades Safe Place(R) Bracelets Using Industry-Leading Infant Security Technology, Fit and Comfort
2. Abbott to Feature Novel Tests and New Upgrades to Testing Platforms at American Association for Clinical Chemistry Lab Expo
3. TeleTracking Upgrades Best-selling TransferCenter™ Software
4. Mylan Announces Settlement Agreement Related to Antidepressant Effexor XR(R)
5. Mylan Receives FDA Approval for Generic Version of Parkinsons Treatment Sinemet(R)
6. Mylan Schedules Third Quarter 2009 Financial Results Conference Call and Live Webcast
7. Mylan Receives FDA Approval for Generic Version of Anticonvulsant Topamax(R) Sprinkle Capsules
8. Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R)
9. Mylan Receives Approval for Generic Version of GoLytely(R)
10. Mylan Declares Quarterly Preferred Stock Dividend
11. Mylan Pre-Pays All Scheduled 2011 Term-Loan Borrowings
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- In a startling report released today, National Safety Council ... comprehensive, proven plan to eliminate prescription opioid overdoses. Prescription ... are tackling the worst drug crisis in recorded U.S. history, assigned ... Kentucky , New Mexico , ... 28 failing states, three – Michigan , ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Issue 52" report to their offering. ... treatment creates a favourable commercial environment for MedImmune to enter. ... base that will serve to drive considerable growth for effective ... serve to cap sales considerably, but development is still in ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma ... as the company,s second affiliate in Latin America . ... ... Astellas Farma Colombia ... ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... Today, InhaleLabs.com (Inhale) offilially launched ... medication by matching users with high quality water pipes within an ideal price range. ... , Inhale was founded by two brothers, Nick and Mike Hunter, who use medical ...
(Date:6/24/2016)... ... ... Dr. Seema Daulat, a native Texan and University of Texas at Austin magna ... 13, 2016. , Dr. Daulat earned her Doctorate of Medicine (MD) at The University ... Agape Clinic serving Dallas’ underprivileged community. , Following medical school, Dr. Daulat completed both ...
(Date:6/23/2016)... ... , ... An article published June 8 on AOL News describes ... cancer in individuals with unhealthy oral hygiene habits. The article goes on to state ... gum disease, brushed their teeth on a daily basis, wore dentures and if they ...
(Date:6/23/2016)... ... June 23, 2016 , ... The Mechille Wilson Agency, a ... Jasper County and the surrounding region, is initiating a charity drive to assist a ... funds earmarked for a scholarship fund that will be presented to the chosen student ...
(Date:6/23/2016)... McKinney, Texas (PRWEB) , ... June 23, 2016 , ... ... the special operations community. He turned towards the water to find peace and set ... funds for a veterans charity and turned to the internet. He came across the ...
Breaking Medicine News(10 mins):